Sickle cell disease: the proportion of liganded haemoglobin needed to prevent crises.
In an attempt to predict the likelihood of successfully treating sickle cell disease by increasing haemoglobin S (HbS) oxygen affinity, two liganded derivatives of Hb S have been studied in an in vitro system that measures deoxy-Hb S polymerization. The participation of these liganded forms in the polymers has been quantitated in terms of an exclusion factor that relates their behaviour to that of deoxy-Hb S. Carbonmonoxy-Hb S has an oxy-Hb-like conformation and did not participate significantly in the polymerization. It was calculated that 30% carbonmonoxy-Hb S would have to be maintained in vivo to prevent sickling. Met-Hb S has a conformational equilibrium intermediate between oxy- (or carbonmonoxy-) and deoxy-Hb S and behaved in a similarly intermediate manner with regard to deoxy-Hb S polymerization. 60% met-Hb S would be needed to prevent in vivo sickling. It is concluded that stabilizing the oxy(R)-conformation is a potentially useful way of preventing sickling, and that a level of 30% R-state Hb S would have to be maintained for this to be successful.
D000755:Anemia, Sickle Cell / Q000097:blood* / Q000188:drug therapy; D001704:Biopolymers; D005782:Gels; D006451:Hemoglobin, Sickle / Q000378:metabolism*; D006801:Humans; D008024:Ligands; D010084:Oxidation-Reduction; D011487:Protein Conformation; D014461:Ultracentrifugation
D001704:Biopolymers; D005782:Gels; D006451:Hemoglobin, Sickle; D008024:Ligands; C038874:carboxyhemoglobin, sickle; C038875:deoxyhemoglobin, sickle; C038876:methemoglobin, sickle